Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

June 4, 2024

https://www.globenewswire.com/news-release/2024/06/04/2893106/15114/en/Lumos-Pharma-Announces-New-Analyses-of-Phase-2-OraGrowtH212-Trial-Presented-at-ENDO-2024.html

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

Follow Us on Social Media

Sign Up for Our Newsletter

A RUM and AI, Please

Midday Market Dispatch- From Eco‑Boards to AI Batteries

Market Spotlight: APLD Powers AI, KDK Rolls Out, FICO Reinvents Scoring—And VENU Amplifies the Concert Economy

Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Nature’s Toughest Fiber

VENU Leads the Intimate Concert Trend with Boutique Venue Solutions

Follow Us on Social Media

Sign Up for Our Newsletter